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We recently reported the case of a retired NFL player with a clinical diagnosis of chronic traumatic encephalopathy (CTE); the diagnosis was based on clinical characteristics of his progressive cognitive disorder and negative \[18F\]-florbetapir PET brain imaging indicating absence of amyloid plaques in his brain (Mitsis *et al.* 2014) ^[@ref-1]^. An \[18F\]-T807 PET imaging study revealed retention of \[18F\]-T807 in the substantia nigra (SN), globus pallidi (GP), and hippocampi, bilaterally. Key images from that paper were reproduced in a recent review by Gandy *et al.* (2014) ^[@ref-2]^. The pattern of retention was interpreted by the original authors as potentially consistent with the clinical diagnosis of CTE ^[@ref-1]^.

The anatomical distribution of \[18F\]-T807 retention was interpreted as atypical and suggestive of the distribution of pathology in Progressive Supranuclear Palsy (PSP). That interpretation was noted in the Mitsis *et al.* (2014) paper ^[@ref-1]^ in light of a recent case report linking CTE and PSP ^[@ref-3]^ and because the subject in the Mitsis *et al.* (2014) ^[@ref-1]^ case manifested nasal speech, hypomimia, and impaired upgaze, all features of PSP. These facts notwithstanding, we emphasize that we cannot exclude the possibility that the pattern of \[18F\]-T807 binding observed in the retired NFL player could be the result of nonspecific retention of \[18F\]-T807 in these same regions of brain. Indeed, some as-yet unpublished experience with \[18F\]-T807 has demonstrated a propensity of the ligand to bind to the SN and GP in what appears to be a non-specific fashion ( <http://www.alzforum.org/news/conference-coverage/tau-tracers-shine-boston-conference>). The \[18F\]-T807 binding to the hippocampi in ^[@ref-1]^ could fall within the spectrum of aging-related tauopathy, the known deposition of NFT in this region ( <http://www.alzforum.org/news/conference-coverage/tau-tracers-shine-boston-conference>). We write here to emphasize the point that proof of the histological underpinnings of \[18F\]-T807 binding awaits the presentation of a sufficiently powered study of *in vivo*-radiological/postmortem-histological correlation relationships, and as a reminder that while the development of several putative tau-binding ligands has opened new possibilities for research and clinical use, that none have been validated to the extent necessary for reliable use and such validation should be a top priority.
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In this letter, the authors describe an alternative explanation of \[ ^18^F\]T807 PET findings in patients with chronic traumatic encephalopathy (CTE). A striking article by [Mitsis *et al.* (2014)](http://www.ncbi.nlm.nih.gov/pubmed/25226550) has suggested the potential usefulness of tau PET imaging for the early detection of tau deposits in patients with CTE. The authors of the letter state that tracer signals in the substantia nigra and globus pallidus might be the result of nonspecific retention of \[ ^18^F\]T807. However, the amount of hippocampal \[ ^18^F\]T807 retention (SUVR 1.45) was considerably higher than the values that have been previously reported in healthy controls, suggesting the involvement of the hippocampus in this patient. It is important to confirm whether the hippocampal \[ ^18^F\]T807 retention was within normal age-appropriate levels or whether it reflected CTE tau lesions in this case. Furthermore, the current findings should be confirmed by postmortem examinations in the future.
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This timely letter by Drs Gandy and DeKosky sheds light onto the inherent difficulties of using not yet fully characterized imaging markers where lack of validation of the tracers used, coupled with limited experience in an emergent field, might potentially lead to over- or under-interpretation of the results, especially when no controls are available to juxtapose the findings. This in turn might reflect badly on the value of this new approach. Larger cohort studies and, as the authors point out, neuropathological confirmation of the imaging findings will be required to fully validate and characterize the binding of these new and essential markers for the  *in vivo* imaging of tau deposits in the brain.
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